Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillusand Rhizopus, and synergy testing for Rhizopus

Medical Mycology

Volumn 46, Issue 6, 2008, Pages 567-573

  Arikan, Sevtap ^a   Sancak, Banu ^a   Alp, Sehnaz ^a   Hascelik, Gulsen ^a   Mcnicholas, Paul ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungal susceptibility test; Aspergillus; Checkerboard; Rhizopus

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CONTROLLED STUDY; DILUTION; DRUG POTENCY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RHIZOPUS; RHIZOPUS ORYZAE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG SYNERGISM; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; PYRIMIDINES; RHIZOPUS; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; RHIZOPUS; RHIZOPUS ORYZAE;

EID: 51649084586     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780801975576     Document Type: Article

References (38)

1. Walsh, TJ, Groll, A. Hiemenz, J. et al. (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect, 10, pp. 48-66.
2. Brakhage, AA. (2005) Systemic fungal infections caused by Aspergillus species: Epidemiology, infection process and virulence determinants. Curr Drug Targets, 6, pp. 875-886.
3. Kontoyiannis, DP, Lionakis, MS Lewis, RE et al. (2005) Zygomycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infec Dis, 191, pp. 1350-1360.
4. Greenberg, RN, Scott, LJ, Vaughn, HH and Ribes, JA. (2004) Zygomycosis (mucormycosis): Emerging clinical importance and new treatments. Curr Opin Infect Dis, 17, pp. 517-525.
5. Chandrasekar, PH. (2005) Antifungal resistance in Aspergillus. Med Mycol, 43, p. S295.
6. Sun, QN, Fothergill, AW, McCarthy, DI, Rinaldi, MG and Graybill, JR. (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother, 46, pp. 1581-1582.
7. Guinea, J., Pelaez, T., Alcala, L., Ruiz-Serrano, MJ and Bouza, E. (2005) Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: Analysis by site of isolation. Antimicrob Agents Chemother, 49, pp. 3495-3497.
8. Diekema, DJ, Messer, SA, Hollis, RJ, Jones, RN and Pfaller, MA. (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 41, pp. 3623-3626.
9. Singh, J., Rimek, D. and Kappe, R. (2005) In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses, 48, pp. 246-250.
10. Dannaoui, E., Meletiadis, J., Mouton, JW, Meis, J. and Verweij, PE. (2003) In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother, 51, pp. 45-52.
11. Herbrecht, R., Denning, DW Patterson, TF et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, pp. 408-415.
12. Imhof, A., Balajee, SA, Fredricks, DN, Englund, JA and Marr, KA. (2004) Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis, 39, pp. 743-746.
13. Torres, HA, Hachem, RY, Chemaly, RF, Kontoyiannis, DP and Raad, II. (2005) Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis, 5, pp. 775-785.
14. Keating, GM. (2005) Posaconazole. Drugs, 65, pp. 1553-1567.
15. Farowski, F., Vehreschild, JJ and Cornely, OA. (2007) Posaconazole: A next-generation triazole antifungal. Future Microbiol, 2, pp. 231-243.
16. Lewis, RE and Kontoyiannis, DP. (2005) Micafungin in combination with voriconazole in Aspergillus species: A pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother, 56, pp. 887-892.
17. Dannaoui, E., Lortholary, O. and Dromer, F. (2004) In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother, 48, pp. 970-978.
18. Kontoyiannis, DP and Lewis, RE. (2003) Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resist Update, 6, pp. 257-269.
19. Heyn, K., Tredup, A., Salvetmoser, S. and Muller, FMC. (2005) Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother, 49, pp. 5157-5159.
20. Philip, A., Odabasi, Z. Rodriguez, J. et al. (2005) In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother, 49, pp. 3572-3574.
21. Cuenca-Estrella, M., Gomez-Lopez, A. Garcia-Effron, G. et al. (2005) Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother, 49, pp. 1232-1235.
22. Arikan, S., Lozano-Chiu, M., Paetznick, V. and Rex, JH. (2002) In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother, 46, pp. 245-247.
23. Dannaoui, E., Afeltra, J., Meis, J. and Verweij, PE. (2002) In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother, 46, pp. 2708-2711.
24. Larone, DH. (1995) Medically Important Fungi-A Guide to Identification, ASM Press, Washington, DC
25. National Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard NCCLS document M38-A, Wayne, PA
26. National Committee for Clinical Laboratory Standards (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard NCCLS document M27-A2, Wayne, PA
27. Eliopoulos, GM and Moellering, RC. (1991) Antimicrobial combinations, pp. 432-492. Williams & Wilkins, Baltimore, MD
28. Johnson, MD, MacDougall, C., Ostrosky-Zeichner, L., Perfect, JR and Rex, JH. (2004) Combination antifungal therapy. Antimicrob Agents Chemother, 48, pp. 693-715.
29. Manavathu, EK, Cutright, JL, Loebenberg, D. and Chandrasekar, PH. (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother, 46, pp. 229-234.
30. Gil-Lamaignere, C., Hess, R. Salvenmoser, S. et al. (2005) Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother, 55, pp. 1016-1019.
31. Arikan, S., Lozano-Chiu, M., Paetznick, V., Nangia, S. and Rex, JH. (1999) Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol, 37, pp. 3946-3951.
32. Sabatelli, F., Patel, R. Mann, PA et al. (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother, 50, pp. 2009-2015.
33. Cuenca-Estrella, M., Gomez-Lopez, A. Mellado, E. et al. (2006) Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother, 50, pp. 917-921.
34. Pfaller, MA, Messer, SA, Mills, K., Bolmstrom, A. and Jones, RN. (2001) Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. J Clin Microbiol, 39, pp. 3952-3954.
35. Diekema, DJ, Messer, SA Hollis, RJ et al. (2007) Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J Clin Microbiol, 45, pp. 1974-1977.
36. Pfaller, MA, Messer, SA, Boyken, L., Hollis, RJ and Diekema, DJ. (2003) In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagn Microbiol Infect Dis, 45, pp. 241-244.
37. Messer, SA, Diekema, DJ Hollis, RJ et al. (2007) Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol., 45, pp. 1322-1324.
38. Najvar, LK, Cacciapuoti, A. Hernandez, S. et al. (2004) Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories. Antimicrob Agents Chemother, 48, pp. 758-764.